Hypersensitivity reactions to oxaliplatin in two Asian patients

Annals of Pharmacotherapy

Volumn 39, Issue 6, 2005, Pages 1114-1118

  Ng, Christina V T ^a  

^a UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

Author keywords

Asian ethnicity; Oxaliplatin hypersensitivity

Indexed keywords

CHLORPHENIRAMINE; DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; HYDROCORTISONE; METOCLOPRAMIDE; OXALIPLATIN; SCOPOLAMINE BUTYL BROMIDE;

ABDOMINAL CRAMP; ADULT; ARTICLE; ASIAN; CASE REPORT; CLINICAL FEATURE; COLORECTAL CANCER; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; ERYTHEMA; FEMALE; HEART PALPITATION; HUMAN; HYPOTENSION; METASTASIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROPHYLAXIS; PRURITUS; SHIVERING; TACHYCARDIA; VOMITING;

ADULT; ANTI-ALLERGIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CHINA; CHLORPHENIRAMINE; COLORECTAL NEOPLASMS; DRUG HYPERSENSITIVITY; FEMALE; FLUOROURACIL; HUMANS; HYDROCORTISONE; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALAYSIA; ORGANOPLATINUM COMPOUNDS; PREGNANCY; TREATMENT OUTCOME;

EID: 18844416402     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E631     Document Type: Article

References (24)

1. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan R, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan-fluorouracil-leucovorin: interim results of a phase 3 trial. J Clin Oncol 2003;21:2059-69.
2. Delaunoit T, Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Findlay BP, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:22-30.
3. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51.
4. Brandi G, Pantaleo MA, Galli C, Falcone A, Antonuzzo A, Mordenti P, et al. Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer 2003;89:477-81.
5. Meyer L, Zuberbier T, Worm M, Oettle H, Riess H. Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule. J Clin Oncol 2002;20:1146-7.
6. Lenz G, Hacker UT, Kern W, Schalhorn A, Hiddemann W. Adverse reactions to oxaliplatin: a retrospective study of 25 patients in one institution. Anti-Cancer Drugs 2003;14:731-3.
7. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
8. Tournigand C, Maindrault-Goebel F, Louvet C, de Gramont A, Krulik M. Severe anaphylactic reactions to oxaliplatin. Eur J Cancer 1998;34:1297-8.
9. Qureshi KM, Leichman C, Berdzik J, O'Connor T, Muffley M, Fakih M, et al. Incidence of hypersensitivity reactions to oxaliplatin at Roswell Park Cancer Institute (RPCI) and protocol for desensitization (abstract). Proc Am Soc Clin Oncol 2003;22:789.
10. Misset JL. Oxaliplatin in practice. Br J Cancer 1998;77(suppl 4):4-7.
11. Santini D, Tonini G, Salerno A, Vincenzi B, Patti G, Dicuonzo G, et al. Idiosyncratic reaction after oxaliplatin infusion. Ann Oncol 2001;12:132-3.
12. Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 2003;24:253-62.
13. Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 1999;17:1141-5.
14. Markman M, Zanotti K, Kulp B, Peterson G. Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity. Gynaecol Oncol 2003;89:514-6.
15. Alliot C, Messouak D, Beets C. Severe anaphylactic reaction to oxaliplatin (letter). Clin Oncol 2001;13:236.
16. Markman M, Zanotti K, Peterson G, Kulp B, Webster K, Belinson J. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol 2003;21:4611-4.
17. Garufi C, Cristaudo A, Vanni B, Bria E, Aschelter AM, Santucci B, et al. Skin testing and hypersensitivity reactions to oxaliplatin. Ann Oncol 2003;14:497-8.
18. Thomas RR, Quinn MG, Schuler B, Grem JL. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 2003;97:2301-7.
19. Goldberg A, Confino-Cohen R, Fishman A, Beth Y, Altaras M. A modified, prolonged desensitization protocol in carboplatin allery. J Allergy Clin Immunol 1996;98:841-3.
20. Gammon D, Bhargava P, McCormick M. Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol. Oncologist 2004;9:546-9.
21. Lim KH, Huang MJ, Lin HC, Su YW, Chang YF, Lin J, et al. Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule. Anti-Cancer Drugs 2004;15:605-7.
22. Hsuen EL, Lim RSC, Wu TS, Kong HL. Oxaliplatin/fluorouracil/leucovorin in advanced colorectal carcinoma: an Asian experience. Ann Pharmacother 2003;37:1909-12. DOI 10.1345/aph.1D153
23. Goh BC, Lehnert ML, Lim HL, Ng AW, Chan CC, Kong HL, et al. Phase 2 trial of docetaxel in Asian patients with inoperable stage 3 non-small cell lung cancer. Acta Oncol 2000;39:225-9.
24. Wood AJJ. Racial differences in response to drugs - pointers to genetic differences. N Engl J Med 2001;344:1393-6.